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Upon HIV infection diagnosis, an 8-month-old boy was transferred for evaluation of worsening respiratory distress requiring
mechanical ventilation. Pneumocystis jirovecii pneumonia (PCP) was diagnosed; the boy also had a nonhealing ulcer at the
site of vaccination with Statens Serum Institut (Danish strain) Bacillus Calmette-Gue´rin (BCG) vaccine and associated axillary
lymphadenopathy. PCP treatment resulted in weaning frommechanical ventilation. Antimycobacterial treatment was immediately
attempted butwas discontinued because of hepatotoxicity. Over severalmonths, he developed splenic lesions and then disseminated
skin and cystic bone lesions. M. bovis was repeatedly cultured from both skin and bone lesions despite various multidrug
antimycobacterial regimens which included linezolid. Eventually, treatment with a regimen of rifabutin, isoniazid, ethambutol,
and linezolid led to definitive cure. Clinicians should consider a linezolid-containing regimen for treatment of severe disseminated
BCG infection, especially if other drug regimens have failed. Although drug toxicity is a particular concern for young children,
this patient received linezolid for 13 months without serious toxicity. This case also highlights the need for universal screening
among pregnant women to prevent vertical transmission of HIV. Finally, routine immunization with BCG vaccine at birth should
be questioned in countries with low and declining burden of tuberculosis.
1. Introduction
Disseminated Bacillus Calmette-Gue´rin (BCG) infection
after vaccination has a high mortality rate and occurs mostly
in patients with immunologic deficiency [1]. Infants infected
with human immunodeficiency virus (HIV) are particularly
susceptible [2]. In Croatia, children receive routine BCG
vaccine at birth (99% coverage) [3], but it is contraindicated
in HIV-exposed infants. However, there is no routine HIV
testing of pregnant women in Croatia as vertical HIV trans-
mission is rare and only 14 children have been perinatally
infected since 1985 [4].We report a case of disseminated BCG
infection with cystic bone lesions in an HIV-infected child.
The child was successfully cured after long-term therapy
with an antimycobacterial regimen including rifabutin and
linezolid.
2. Case Presentation
After HIV infection was diagnosed, an 8-month-old boy
with worsening pneumonia and respiratory distress was
transferred to the University Hospital for Infectious Diseases,
Zagreb, Croatia (UHID), on November 4, 2011.The child had
previously been hospitalized two times in his local hospital
for diarrhoea and pneumonia. His mother had not been
tested for HIV while pregnant. There was no family history
of tuberculosis (TB), but immunization with Statens Serum
Hindawi Publishing Corporation
Case Reports in Infectious Diseases
Volume 2016, Article ID 1528981, 6 pages
http://dx.doi.org/10.1155/2016/1528981
2 Case Reports in Infectious Diseases
Institut (Danish strain) BCG vaccine at birth had left a
nonhealing ulcer on the deltoid region of the left arm.
On presentation, the infant was receiving mechanical
ventilation and was overall in poor condition. He weighed
7.4 kg and was 42.5 cm long. On physical examination he
had tachycardia, hepatosplenomegaly, and oedema of the
lower extremities. There was also an ulcer at the site of BCG
immunization with a palpable ipsilateral 1 cm axillary lymph
node. His chest X-ray showed diffuse bilateral interstitial
infiltrates with a slightly enlarged cardiac silhouette.
Results of laboratory studies on admission showed an
erythrocyte sedimentation rate of 5mm per first hour, serum
procalcitonin level of 0.844 𝜇g/L, hemoglobin concentration
of 130 g/L, leukocyte count of 10.4 × 109/L, and platelet count
of 51 × 109/L. His CD4 cell count was 5.9% (24 cells per
𝜇L) and his plasma HIV-1 RNA was 4.96million copies/mL.
An overview of the major clinical and laboratory findings is
presented on Figure 1.
He was immediately given high-dose co-trimoxazole
and steroids for presumed Pneumocystis jirovecii pneumo-
nia as well as piperacillin-tazobactam for probable hospital
acquired infection. Anti-TB therapy consisting of isoniazid,
ethambutol, and rifampicin, which had been started the day
before transfer to our hospital, was continued. On the third
hospital day at UHID he developed signs of hepatitis; his
serum bilirubin climbed to 116.5 𝜇mol/L (conjugated biliru-
bin 66.9 𝜇mol/L), his aspartate aminotransferase (AST) was
1952 IU/L, his alanine aminotransferase (ALT) was 365 IU/L,
and his lactate dehydrogenase level was 2948 IU/L. His
prothrombin time was prolonged (international normalized
ratio value 2.7). All TB medications were stopped and liver
function tests gradually returned to normal over the next
three weeks.
Tracheal aspirate taken on the day of admission was
positive for Pneumocystis jiroveciiDNA on polymerase chain
reaction and also grew Pseudomonas aeruginosa on culture.
Antiretroviral therapy (ART) was started two weeks after
admission to UHID with a combination of zidovudine, lami-
vudine, and lopinavir/ritonavir. There was no HIV drug
resistance found in the blood sample obtained prior to ini-
tiation of ART. Steroids were stopped after 21 days of therapy
and at that point co-trimoxazole was switched to a prophylac-
tic oral dose. The breathing had significantly improved so he
wasweaned frommechanical ventilation 4weeks after admis-
sion to our hospital. We performed an interferon-gamma
release assay (QuantiFERON); the result was negative. In
light of the clinical improvement and prior signs of severe,
presumably toxic hepatitis, the decision was made not to give
TB treatment.
Two months after admission an abdominal ultrasound
revealed multiple small (up to 8mm) hypoechogenic splenic
lesions. Two weeks later signs of BCG infection were again
present with prominent ipsilateral axillary lymph node
enlargement. An attempt was made to restart anti-TB medi-
cations. However, an urticarial rash developed after isoniazid
was started, so the drug was discontinued; the patient was
treated with amikacin for one week and clarithromycin,
ciprofloxacin, and prednisolone for 4 weeks. This treatment
regimen led to regression in lymph node size. At this
time, zidovudine was replaced by abacavir due to anaemia
(Figure 1).
In the fourth month of care, the child developed multiple
skin lesions on his head and limbs that started as erythe-
matous papules and turned into subcutaneous abscesses. A
repeatedQuantiFERON test was now positive.Mycobacterial
cultures from the disseminated skin lesions were taken and
subsequently grew M. bovis. At this point we learned that
mycobacterial cultures from the site of BCG application (left
deltoid muscle) and tracheal aspirate were taken at the local
hospital about one week prior to transfer to our hospital.
These cultures also grew M. bovis, but the staff at UHID
was not aware of the positive results. Initially the samples
were cultured on solid (Loewenstein and Stonebrink) and
liquid MGIT (Mycobacteria Growth Indicator Tube, the BD
BACTEC MGIT 960 System) media. The identification
of the cultured M. bovis BCG strain was done using the
commercially available line probe assay, GenoType MTBC
Kit (Hain Lifescience, Nehren, Germany).
Drugs with antimycobacterial activity (amikacin, cipro-
floxacin, and azithromycin) were reintroduced (Figure 1).
Multiple cystic bone lesions were noted in the skull and in
the bones of both arms, both hands, and both legs (Figure 2).
As fever and skin lesions persisted, ethambutol, linezolid
(10–12mg/kg orally three times per day), and isoniazid were
sequentially added to his anti-TB regimen (Figure 1). This
time neither rash nor toxic hepatitis developed. Because we
wanted to give rifampicin again and rifabutin was not avail-
able at that time, we replaced lopinavir/ritonavir with nevi-
rapine. However, two weeks later there was an increase in
serum liver enzymes (AST 113 IU/L and ALT 122 IU/L), so
nevirapinewas stopped and standard dose lopinavir/ritonavir
was reintroduced. Amikacin, azithromycin, ciprofloxacin,
and ethambutol were discontinued as shown in Figure 1.
After a 10-month hospital stay the patient was discharged on
linezolid, isoniazid, abacavir, lamivudine, and lopinavir/rito-
navir.
However, fever reappeared, new skin lesions were still
developing, and bone lesions were growing. A bone biopsy of
the right tibia was done on 12th month of care at UHID (Fig-
ure 1). Histopathological findings revealed inflammatory tis-
sue with microscopic characteristics of granulomata and foci
of necrosis, which grew acid-fast bacilli identified asM. bovis.
At this point ethambutol and rifabutin (dosed at 5mg/kg
three times perweek)were added to theTB regimen, and after
six weeks the frequency of rifabutin dosing was increased to
daily administration (once daily 7 days per week) (Figure 1).
After rifabutin was given dosed at 5mg/kg/day every day the
patient remained without fever. The child’s complete blood
count wasmonitored; after rifabutinwas given 3 times weekly
his lowest observed leukocyte count was 4.1 × 109/L with an
absolute neutrophil count (ANC) of 1.3 × 109/L (1300 per 𝜇L)
on the 18th day of administration. After rifabutin was given
daily, the lowest leukocyte count was observed after one
month of therapy (1.9 × 109/L with an ANC of 0.7 × 109/L
(700 per 𝜇L)). However, this neutropenia was transient; after
six days the ANC was 3300 per 𝜇L without any intervention.
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Figure 1: Major events, CD4 cell count and viral load measurements, antiretroviral therapy, and antimycobacterial therapy during the course
of the disease. (a) Pneumocystis jiroveci pneumonia; culture of tracheal aspirate M. bovis positive; liver failure, antituberculosis therapy
stopped; QuantiFERON TB test negative; ART started. (b) Hypoechogenic splenic lesions seen on ultrasound. (c) Necrotic lymph nodes
seen on ultrasound; urticarial rash, after isoniazid reintroduction. (d) Disseminated skin lesions (M. bovis cultured); QuantiFERON TB test
positive; blood culture for M. bovis negative; cystic bone lesions. (e) Lopinavir/ritonavir replaced by nevirapine for 2 weeks. (f) Tibial bone
biopsy culture forM. bovis positive. (g) Leg abscess culture forM. bovis positive. (h) Skin lesion and lymph node culture forM. bovis negative.
(i) Antimycobacterial therapy stopped. VL, viral load (HIV-1 RNA); ART, antiretroviral therapy; ZDV, zidovudine; 3TC, lamivudine; LOPr,
lopinavir/ritonavir; ABC, abacavir; RAL, raltegravir; 3/w, three times weekly; TB, tuberculosis.
(a) (b)
Figure 2: Disseminated Bacillus Calmette-Gue´rin (BCG) infection of the upper and lower extremities in an infant produces similar images
(June–September 2012). (a) Bilateral lateral and anteroposterior conventional radiographs of the lower parts of both legs show multiple
radiolucent cystic lytic areas of bone destruction with minimal periosteal reaction and bone widening in the distal diaphysis of tibia and
fibula. (b) Conventional posteroanterior radiographs of both hands revealed periosteal elevation and multiple small lytic lesions with bone
widening in the proximal phalanges of the fourth fingers bilaterally.
Since the response to ART was not optimal (Figure 1), a
resistance test was done which showed reverse transcriptase
mutations associated with nevirapine (Y181C) and lamivu-
dine (M184V) resistance (16th month of care). To optimize
the virological response to ART, abacavir was replaced
by zidovudine and raltegravir granules were added to the
antiretroviral regimen. After 16 months in care a skin lesion
and a lymph node aspirate failed to growmycobacteria for the
first time, and one month later the child became consistently
afebrile. At this point ethambutol treatment had reached 6
months, and it was discontinued. Two months later linezolid
was stopped after a total of 13 months of therapy. At follow-
up 12 months from the first negative skin lesion culture the
child was clinically stable and radiographs of the lower limb
showed signs of bone healing. Anti-TB therapywas stopped at
this time (Figure 1).The child reached an undetectable HIV-1
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RNA viral loadmeasured by the Abbott assay (detection limit
40 copies/mL) only after 36 months of ART on a regimen of
tenofovir, lamivudine, lopinavir/ritonavir, and raltegravir.
3. Discussion
Our case report demonstrates the range of difficulties and
challenges in the management of disseminated M. bovis
infection in an HIV-infected infant. Other opportunistic
infections can be present as evidenced by the severe, life-
threatening Pneumocystis jirovecii pneumonia in our patient.
Drug toxicities from first line anti-TB drugs occurred, and
less effective regimens needed to be given. Nonetheless,
despite these toxicities every attempt should be made to
reintroduce themost potent anti-TBdrugs. Pharmacotherapy
is complicated in HIV-infected infants and small children
because of the limited number of antiretroviral drug formula-
tions, drug interactions with rifampicin, and drug toxicities.
There is also little clinical experience in childrenwith the dos-
ing of rifabutin when combined with lopinavir/ritonavir. A
pharmacokinetic study in children without tuberculosis pub-
lished in 2015 showed that rifabutin dosed at 5mg/kg three
times per week resulted in lower exposure values to rifabutin
compared to adults receiving 150mg of rifabutin daily [5].
In our child, after the dosing of rifabutin was increased
to 5mg/kg daily 7 days per week no recurrencies of fever
were observed. So, our experience would suggest that daily
administration of rifabutin at 5mg/kg might be appropriate.
Similarly to the study byMoultrie et al. [5], we observed neu-
tropenia during rifabutin therapy; however, it was transient
and did not require discontinuation of the drug or a change
in dosing frequency. Instead of rifabutin our child could have
received “super-boosted lopinavir/ritonavir” with rifampicin.
In a pharmacokinetic study, children treated with ritonavir in
addition to doses of coformulated lopinavir/ritonavir (super-
boosted lopinavir/ritonavir) while on rifampicin-based treat-
ment achieved serum concentrations of lopinavir compar-
able to those of children treated with standard dose lopinavir/
ritonavir in the absence of rifampicin [6]. Based on retrospec-
tive clinical observations, virologic response among children
receiving super-boosted lopinavir and rifampicin appeared
to be similar to that of children receiving standard dose
lopinavir/ritonavir without tuberculosis treatment [7]. In
our child, super-boosted lopinavir/ritonavir was not given
together with rifampicin mainly because ritonavir in the
liquid form was not available in Croatia. Because our patient
experienced hepatotoxicity when given rifampicin and later
also on nevirapine, we were also concerned that hepatotoxic-
ity might develop if rifampicin was given with super-boosted
lopinavir/ritonavir.
ART-induced immune recovery may unmask or worsen
existingM. bovis infection. As in our example, it is sometimes
difficult to judge whether the worsening and persistence of
the disease represent an uncontrolled active infection or an
immune reconstitution syndrome.
Children in Croatia are routinely immunized with an
attenuated BCG strain of Mycobacterium bovis at birth to
prevent tuberculosis.DisseminatedBCG infection is themost
serious complication of BCG vaccination, with an incidence
around one in one million vaccine recipients and mortality
rate over 50% in those that develop serious complications
[8, 9]. It almost always occurs in patients with immunode-
ficiency disorders, especially cell-mediated immune defects
such as severe combined immunodeficiency, chronic gran-
ulomatous disease, and HIV infection [1]. Our patient
presented with relapsing fever, failure to thrive, and hep-
atosplenomegaly, which are among the most commonly
reported symptoms of disseminated BCG infection. He also
developed multiple skin abscesses and, later in the course of
disease, multiple bone lesions. M. bovis was repeatedly cul-
tured from both skin and bone lesions and showed the usual
susceptibility pattern of being resistant only to pyrazinamide.
This patient had lesions in the long bones of the extremities, as
commonly seen in disseminated infection, but also had skull
lesions, which is not a common finding [10]. New skin lesions
appeared despite combined anti-TB treatment until first
line anti-TBdrugswere reintroduced.Althoughdisseminated
BCG infection (including cases with multiple bone lesions)
are often seen in children with severe combined immunode-
ficiency, reports of similar cases in HIV-infected children are
scarce [11–13].
According to the revised pediatric classification of BCG
disease proposed by Hesseling et al. [11], our patient had local
skin disease that progressed to distant disease (pulmonary
involvement) and then disseminated disease (skin and bone
involvement). The disseminated disease unfolded after a rise
in CD4 cell count and a drop in HIV-1 RNA viral load sug-
gesting a role for immune reconstitution.The first appearance
of extrapulmonary BCG infection (hypoechogenic splenic
lesions) was noted 8 weeks after starting ART and coin-
cided with an increase in the CD4 lymphocyte cell count.
However, one may argue that the worsening of symptoms
was primary due to the inadequate TB treatment and not to
immune reconstitution. The interferon-gamma release assay
(QuantiFERON) is believed not to be affected by M. bovis
infection. However, the positive test at the time of immune
recovery suggests that a false positive test may occur in some
circumstances. Cases of BCG-induced immune reconstitu-
tion syndrome have been described inHIV-infected children,
but all reported cases in the English medical literature
describe only localized suppurative disease [14, 15].
Linezolid is currently used mainly for the treatment
of infections caused by resistant Gram-positive bacteria.
Although the use of linezolid for mycobacterial infections is
increasing, the World Health Organization categorizes line-
zolid as group 5 anti-TB agent with unclear efficacy or con-
cerns regarding usage [16]. Linezolid has shown in vitro activ-
ity against Mycobacterium tuberculosis [17]. Another study
reported similar linezolid MIC values of M. bovis and M.
tuberculosis isolates (0.5mg/L), suggesting susceptibility to
linezolid [18]. In vivo studies described dose-dependent
activity of linezolid in a murinemodel of TB and limited bac-
tericidal activity in mice [19, 20]. One in vitro study showed
that linezolid had synergistic activity with rifampicin but not
with the fluoroquinolones in M. tuberculosis infection [21],
while multiple studies in mice reported antagonistic activity
with isoniazid, rifampicin, and pyrazinamide [22]. However,
an increasing number of case reports and studies present
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good results with linezolid-containing regimens for the
treatment of drug-resistant M. tuberculosis infection in both
adults and children [23–27]. Our patient improved clinically
after linezolid was added to the treatment regimen, but he
still had periods of low-grade fever and developed new skin
and bone lesions. The addition of rifabutin to the anti-TB
regimen eventually resulted in complete cure of the infection.
Although linezolid has a good safety profile, long-term treat-
ment increases the likelihood of side-effects, especially bone
marrow suppression, which sometimes requires cessation
of therapy [28]. Other serious side-effects are optic and
peripheral neuropathy. Our patient received linezolid for
more than a year and required red blood cell transfusions
three times during linezolid therapy. However, because of the
severity of the disease and other concomitant medications
(co-trimoxazole), it is unlikely that linezolid was the main
cause of anaemia. Moreover, blood transfusions were given
early during linezolid therapy; when co-trimoxazole was
stopped there was a significant improvement in red blood cell
count with no further need for additional blood transfusions
despite continued treatment with linezolid.
Universal BCG vaccination is common in the world;
157 countries recommended it in 2010 [3]. However, given
the constantly declining rates of TB in Croatia, [29] it may
be appropriate to abandon universal BCG vaccination of
newborns in Croatia as well as in other countries with
declining and low TB incidence. To avoid cases of dissem-
inated BCG disease caused by vaccination of newborns, it
is important to know the HIV status of the mother and the
newborn. Had HIV infection in the mother been diagnosed
during pregnancy, the BCG vaccine would not have been
given until HIV infection in the newborn was ruled out
and vertical HIV transmission to the child could have also
been prevented by antiretroviral treatment and prophylaxis.
Our case highlights the need for universal HIV screening
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